BMI View: Improvements in Colombia''s pharmaceutical regulation system will expand local patients''access to medicines. However, it will also put pricing pressures on drugmakers, and promote the use ofgeneric versions, which will undermine the growth of patented drug market. Nevertheless, BMI expectsmore foreign pharmaceutical companies to invest in Colombia, capitalising on the country''s strong longtermgrowth prospects.Headline Expenditure Projections?? Pharmaceuticals: COP7,076bn (US$3.83bn) in 2011 to COP7,612bn (US$4.23bn) in 2012;+7.6% in local currency terms and +10.4% in US dollar terms. Forecast broadly in line withQ412.?? Healthcare: COP29,953...
No comments:
Post a Comment